» Articles » PMID: 22841546

Disruption of Inducible 6-phosphofructo-2-kinase Impairs the Suppressive Effect of PPARγ Activation on Diet-induced Intestine Inflammatory Response

Overview
Journal J Nutr Biochem
Date 2012 Jul 31
PMID 22841546
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

PFKFB3 is a target gene of peroxisome proliferator-activated receptor gamma (PPARγ) and encodes for inducible 6-phosphofructo-2-kinase (iPFK2). As a key regulatory enzyme that stimulates glycolysis, PFKFB3/iPFK2 links adipocyte metabolic and inflammatory responses. Additionally, PFKFB3/iPFK2 is involved in the effect of active PPARγ on suppressing overnutrition-induced adipose tissue inflammatory response, which accounts for the insulin-sensitizing and antidiabetic effects of PPARγ activation. Using PFKFB3/iPFK2-disrupted mice, the present study investigated the role of PFKFB3/iPFK2 in regulating overnutrition-associated intestine inflammatory response and in mediating the effects of PPARγ activation. In wild-type mice, intestine PFKFB3/iPFK2 was increased in response to high-fat diet (HFD) feeding compared with that in mice fed a low-fat diet. However, intestine PFKFB3/iPFK2 was decreased in PFKFB3/iPFK2-disrupted mice and did not respond to HFD feeding. Furthermore, on an HFD, PFKFB3/iPFK2-disrupted mice displayed a significant increase in major intestine proinflammatory indicators such as toll-like receptor 4 expression, c-Jun N-terminal kinase 1 and nuclear factor kappa B phosphorylation, and proinflammatory cytokine expression compared with wild-type littermates. Upon treatment with rosiglitazone, an agonist of PPARγ, intestine proinflammatory indicators were markedly decreased in wild-type mice, but to a much lesser degree in PFKFB3/iPFK2-disrupted mice. Overall, the status of HFD-induced intestine inflammatory response in all treated mice correlated inversely with systemic insulin sensitivity, indicated by the homeostasis model assessment of insulin resistance data. Together, these results suggest that PFKFB3/iPFK2 is critically involved in the effect of PPARγ activation on suppressing diet-induced intestine inflammatory response.

Citing Articles

Distinct tumor-TAM interactions in IDH-stratified glioma microenvironments unveiled by single-cell and spatial transcriptomics.

Motevasseli M, Darvishi M, Khoshnevisan A, Zeinalizadeh M, Saffar H, Bayat S Acta Neuropathol Commun. 2024; 12(1):133.

PMID: 39148129 PMC: 11328419. DOI: 10.1186/s40478-024-01837-5.


Mini review: STING activation during non-alcoholic fatty liver disease.

Li H, Guo X, Aquino E, Wu C Front Nutr. 2023; 10:1139339.

PMID: 36937350 PMC: 10014842. DOI: 10.3389/fnut.2023.1139339.


The Protective Effects of Iron Free Lactoferrin on Lipopolysaccharide-Induced Intestinal Inflammatory Injury via Modulating the NF-κB/PPAR Signaling Pathway.

Wu H, Fan L, Gao Y, Wang J, Zheng N Foods. 2022; 11(21).

PMID: 36359991 PMC: 9658706. DOI: 10.3390/foods11213378.


Obesity elicits a unique metabolomic signature in human airway smooth muscle cells.

Xu S, Karmacharya N, Cao G, Guo C, Gow A, Panettieri Jr R Am J Physiol Lung Cell Mol Physiol. 2022; 323(3):L297-L307.

PMID: 35787188 PMC: 9514806. DOI: 10.1152/ajplung.00132.2022.


Parsing the Role of PPARs in Macrophage Processes.

Toobian D, Ghosh P, Katkar G Front Immunol. 2022; 12:783780.

PMID: 35003101 PMC: 8727354. DOI: 10.3389/fimmu.2021.783780.


References
1.
Wu C, Khan S, Peng L, Li H, Carmella S, Lange A . Perturbation of glucose flux in the liver by decreasing F26P2 levels causes hepatic insulin resistance and hyperglycemia. Am J Physiol Endocrinol Metab. 2006; 291(3):E536-43. DOI: 10.1152/ajpendo.00126.2006. View

2.
Grundy S . Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy. Nat Rev Drug Discov. 2006; 5(4):295-309. DOI: 10.1038/nrd2005. View

3.
Lehmann J, Moore L, Wilkison W, Willson T, Kliewer S . An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem. 1995; 270(22):12953-6. DOI: 10.1074/jbc.270.22.12953. View

4.
Phillips L, Grunberger G, Miller E, Patwardhan R, Rappaport E, Salzman A . Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes. Diabetes Care. 2001; 24(2):308-15. DOI: 10.2337/diacare.24.2.308. View

5.
Adachi M, Kurotani R, Morimura K, Shah Y, Sanford M, Madison B . Peroxisome proliferator activated receptor gamma in colonic epithelial cells protects against experimental inflammatory bowel disease. Gut. 2006; 55(8):1104-13. PMC: 1513267. DOI: 10.1136/gut.2005.081745. View